Will Payer-Dependent Diagnostics Companies Get Left Behind? Marty Keiser, Founder at IVBH / Mammogen

In this episode of Diagnosing Dx, David Filby is joined by Marty Keiser, Founder and CEO of IVBH.

After beginning his career in asset management and capital markets, Marty moved into biotech eight years ago with a focus on blood-based molecular diagnostics and early disease detection. That outside perspective shaped how he built IVBH, borrowing ideas from industries beyond diagnostics to create a different model for developing and scaling diagnostic companies.

Marty explains IVBH’s studio model, the science behind its cell-free RNA platform, and how its health franchises are developing tests across breast cancer, lung cancer and metabolic liver disease.

We also discuss why traditional diagnostics business models can struggle, the growing opportunity for cash-pay and consumerised testing, and what helped Mammogen secure institutional Series A funding in a difficult market.

Key takeaways:
🔹 Why Marty believes the traditional diagnostics business model needs to evolve
🔹 How IVBH uses a central discovery platform to build multiple health franchises
🔹 Why cell-free RNA could offer advantages for earlier disease detection
🔹 How LDTs, cash-pay models and new diagnostic “storefronts” could reshape commercialisation
🔹 What investors looked for when Mammogen raised its Series A

Chapters:
01:02 Introduction and Marty Keiser’s background
03:22 Moving from capital markets into diagnostics
08:20 Building the IVBH business model differently
11:27 Surviving the biotech downturn and changing capital markets
16:09 The science behind IVBH’s cell-free RNA platform
20:06 LDTs, cash-pay testing and new commercial models
26:13 What helped Mammogen secure its Series A
30:26 Future milestones and rethinking diagnostics growth

Guest: Marty Keiser
Founder & CEO, IVBH
LinkedIn: https://www.linkedin.com/in/martykeiser

Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/

🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.